Dendreon Corp (DNDN)
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
Recs
melj44
(50.11)
Submitted: 11/12/2009 1:19:13 PM :
Start Price:
$28.91
DNDN Score:
-3.31
New phase 3's in the works.
Recs
WAKEUPANDSMELL
(35.43)
Submitted: 11/9/2009 10:05:07 PM :
Start Price:
$29.20
DNDN Score:
-4.19
DRUGS UNDER DEVELOPMENT
Recs
brianpivar
(96.79)
Submitted: 11/9/2009 6:29:43 PM :
Start Price:
$29.20
DNDN Score:
+4.19
terrible fundamentals
Recs
mullings8454
(< 20)
Submitted: 10/30/2009 11:41:33 AM :
Start Price:
$25.84
DNDN Score:
+4.34
Whole new way of treating cancers, with treatment for breast cancer to follow treatment for prostate cancer. No more chemo or radiation. Amazing technology. Acts like a vaccine. Big companies putting big money into it, i.e. Fidelity Mutual Corp.
Recs
truckeeboy
(< 20)
Submitted: 10/21/2009 11:48:36 AM :
Start Price:
$28.76
DNDN Score:
-2.35
Investigational drug ready for FDA approval.
Recs
patentprowler
(52.55)
Submitted: 10/13/2009 10:09:04 AM :
Start Price:
$28.82
DNDN Score:
+5.03
They have a reexam pending on their key drug Provenge (which they have not commented on). If Congress can't agree on some type of market exclusivity, they could have no market protection. They are consequently not a good acquisition target at this time despite popular sentiment.
Recs
keahou
(< 20)
Submitted: 10/10/2009 10:48:33 PM :
Start Price:
$29.39
DNDN Score:
-6.25
A new paradigm in fighting cancer
Recs
PharmaSeer
(< 20)
Submitted: 10/8/2009 12:04:33 PM :
Start Price:
$27.57
DNDN Score:
-0.76
I think this may actually happen in closer to 1 year but will occur by the 24 month point for sure. As a health care professional I can honestly say that the data behind Provenge looks great, and when combined with the lack of side effects mean this agent will likely become a preferred option in its arena. I do not know an single oncologist who won't be trying to use this in earlier stages if they see the same results shown in IMPACT
Recs
lonewulf47638
(61.08)
Submitted: 10/6/2009 6:40:57 AM :
Start Price:
$26.97
DNDN Score:
+0.59
TOO many competers and nom earnings. Rise on news only.
Recs
Recs
Thelmal
(34.48)
Submitted: 9/25/2009 9:26:24 AM :
Start Price:
$26.89
DNDN Score:
-0.27
Doing creative research in the fight against Cancer
Recs
21popsontop
(69.47)
Submitted: 9/20/2009 4:50:23 AM :
Start Price:
$28.63
DNDN Score:
+5.51
Down to the ground we go and where she stops only granny ma shall know. My guess $1.05.Biotech and Cancer cures. Pumps and dumps of a cold hearted market. I'll admit ,I'm guilty as sin but reality always wins in the end. Nothing here but Hype tak'en a flight! Book Value a share $1.40 Revenue a share zilch o mundo ROE minus - 180% Earnings?share minus -$1.75 5 year sales growth minus -67% Free cash flow,ha!ha! Future prospects N/A Famous historical documented events ( A pump and dump.
Recs
stockcommander
(97.69)
Submitted: 9/16/2009 2:32:20 PM :
Start Price:
$26.72
DNDN Score:
-2.19
A decent pullback seems natural at this point
Recs
PearlandTX
(96.63)
Submitted: 8/31/2009 9:47:18 PM :
Start Price:
$23.25
DNDN Score:
-12.60
Huge losses. Weak balance sheet. Recent price escalation seems to be due to speculation and unrelated to business fundamentals. May need to dig further to see if they recently invented the cure for unhappiness.
Recs
stockgripes
(98.49)
Submitted: 8/26/2009 12:27:21 PM :
Start Price:
$24.63
DNDN Score:
-7.10
Nothing has happened regarding the buyout, I think this will go back to teens again
Recs
clawmann
(79.04)
Submitted: 8/12/2009 7:21:01 AM :
Start Price:
$23.20
DNDN Score:
+10.29
FDA approval followed by large orders.
Recs
MrBuzz111
(85.85)
Submitted: 8/8/2009 4:19:13 PM :
Start Price:
$23.53
DNDN Score:
-9.89
Terribly overbought
Recs
douchrti
(63.87)
Submitted: 7/30/2009 12:03:06 PM :
Start Price:
$24.27
DNDN Score:
+4.92
Up and coming in the fight to prevent cancer.
Recs
ktfoold
(46.27)
Submitted: 7/29/2009 4:39:44 PM :
Start Price:
$24.48
DNDN Score:
+3.17
going to be approved it is a game changer in treating cancer,
Recs
boyceh66
(23.17)
Submitted: 7/28/2009 3:19:24 PM :
Start Price:
$23.99
DNDN Score:
-8.11
Merriman has $50 price target and many analysts think DNDN will be bought out before 2010, and they will have a catalyst from submitting their app to the FDA in a few months...so the stock should outperform market in next 6 months...even though this does not count the huge April run-up. Anybody believe in NewWorldInvestor's $360 price target (not counting dilution vis share issuances)? Pretty interesting...
One must be skittish about long-term hold with DNDN, though, because they want insurance companies to pay about $60,000 per patient after it gets past the FDA and available in the USA market - to only give each patient a few extra months of life before dying. Because there are MANY drugs and treatments that aim to delay death from various cancers by only a few months, and they (almost) all cost tens of thousands per patient, you have to consider Obama and the insurance companies teaming up and targeting this area as a primary cause of PREDICTED/FUTURE healthcare cost growth. They will try to find a way to cut out insurance coverage for these kinds of very expensive treatments. Big ethical debate on the horizon, don't you think?
I hope patients and the economy's stability benefit from the emergence of simpler and cheaper PREVENTIVE treatments like the prostate cancer prevention drug from GTXI, that many folks (the ones who want the drug) can likely pay for themselves on a monthly basis, with only partial insurance co-pay.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 329 1 2 3 4 5 6 7 8 9 10 Next »